Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Biometals ; 34(2): 277-289, 2021 04.
Article in English | MEDLINE | ID: mdl-33389333

ABSTRACT

A new schiff base cobalt(III) complex [N,N'-bis(2'-hydroxyphenylacetone)-o-ethanediamine] cobalt(III) (M3) has been synthesized and characterized by single X-ray crystallography. The cytotoxicity of complex M3 was evaluated against HeLa, LoVo, A549, A549/cis cancer cell lines, and the normal cell lines LO2 by MTT assays. The IC50 is in the range of 6.27-22.68 µM, which is somewhat lower than cisplatin on the basis of platinum molar concentration. Furthermore, anticancer mechanistic studies showed that the complex M3 inhibited cell proliferation by blocking DNA synthesis and then acted on nuclear division of HeLa cells over time. Moreover, western blot analysis indicated M3 dramatically decreased the target protein c-Myc and KLF5 expression levels, and activated many signaling pathways including ER stress, apoptosis, cell cycle and DNA damage in HeLa. M3 did not affect proteasomal activity.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cobalt/pharmacology , Coordination Complexes/pharmacology , Uterine Cervical Neoplasms/drug therapy , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Cell Proliferation/drug effects , Cells, Cultured , Cobalt/chemistry , Coordination Complexes/chemical synthesis , Coordination Complexes/chemistry , Drug Screening Assays, Antitumor , Female , Humans , Schiff Bases/chemistry , Schiff Bases/pharmacology , Uterine Cervical Neoplasms/metabolism , Uterine Cervical Neoplasms/pathology
2.
J Inorg Biochem ; 208: 111103, 2020 07.
Article in English | MEDLINE | ID: mdl-32505045

ABSTRACT

A new Schiff base copper(II) complex [N,N'-bis(2'-hydroxyphenylacetone)-o-ethanediamine] copper (II) (M1) has been synthesized and characterized by single X-ray crystallography. The cytotoxicity of complex M1 was evaluated against HeLa, LoVo, A549, A549/cis cancer cell lines, and the normal cell lines LO2 and HUVEC, by MTT (3-(4,5-dimethylthiazoyl-2-yl)2,5-diphenyltetrazoliumbromide) assays. The IC50 (50% inhibition concentrations) is in the range of 5.13-11.68 µM, which is somewhat lower than cisplatin on the basis of platinum molar concentration. Furthermore, anticancer mechanistic studies showed that the complex M1 inhibited cell proliferation by blocking DNA synthesis and then acted on nuclear division of HeLa cells over time. Moreover, M1 increased intracellular ROS (Reactive oxygen species) levels in a dose-dependent manner. Western blot analysis indicated M1 dramatically decrease c-Myc transcription factor and KLF5 (Krüppel-like factor 5) protein expression levels in HeLa. M1 did not inhibit proteasomal activity. Finally, M1 induced DNA damages and activated the DNA damage repair pathways.


Subject(s)
Antineoplastic Agents , Apoptosis/drug effects , Cell Proliferation/drug effects , Coordination Complexes , Copper , Neoplasms , A549 Cells , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/pharmacology , Coordination Complexes/chemistry , Coordination Complexes/pharmacokinetics , Coordination Complexes/pharmacology , Copper/chemistry , Copper/pharmacokinetics , Copper/pharmacology , HeLa Cells , Human Umbilical Vein Endothelial Cells , Humans , Neoplasms/drug therapy , Neoplasms/metabolism , Neoplasms/pathology , Schiff Bases/chemistry , Schiff Bases/pharmacokinetics , Schiff Bases/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...